A 58-year-old man with a 10-year history of Type 2 diabetes mellitus on metformin and glibenclamide presents with recurrent infections and fatigue. His fasting blood glucose is 240 mg/dL despite medication adherence. Which investigation is most appropriate to assess the adequacy of long-term glycemic control and guide intensification of therapy?

## Assessment of Long-Term Glycemic Control in Type 2 Diabetes **Key Point:** HbA1c is the gold standard investigation for assessing long-term glycemic control and guiding therapeutic decisions in diabetes management. ### Why HbA1c is Superior for Long-Term Assessment HbA1c reflects the average blood glucose concentration over the preceding 2–3 months. Hemoglobin becomes irreversibly glycated at a rate proportional to average blood glucose, providing a reliable marker of glycemic control independent of day-to-day fluctuations. | Investigation | Time Window | Clinical Use | Limitations | |---------------|------------|--------------|-------------| | **Fasting Glucose** | Single point | Screening, diagnosis | Affected by overnight fasting, single-day variation | | **Random Glucose** | Single point | Screening, diagnosis | Highly variable, poor for monitoring | | **HbA1c** | 2–3 months | Monitoring, therapeutic target | Cannot detect acute changes; unreliable in hemolytic anemia, pregnancy | | **Fructosamine** | 2–3 weeks | Short-term monitoring | Less standardized; used in pregnancy or rapid changes | **High-Yield:** HbA1c target for most Type 2 diabetics is <7% (53 mmol/mol). Values >8% indicate need for therapy intensification [cite:ADA Standards of Care 2023]. **Mnemonic:** **HbA1c = Hemoglobin A1c** — the glycated form of hemoglobin that reflects average glucose over 2–3 months. ### Clinical Application in This Case The patient's fasting glucose of 240 mg/dL suggests poor control. HbA1c will: 1. Confirm whether this is a chronic pattern or acute decompensation 2. Guide intensification (e.g., adding a third agent or insulin) 3. Assess risk for microvascular complications **Clinical Pearl:** A single fasting glucose measurement can be misleading; HbA1c provides the true picture of glycemic control and is essential before escalating therapy.